← Back to Companies

Annexon Biosciences

Clinical-stage biopharmaceutical company developing therapeutics targeting the complement system C1q protein for neurological and ophthalmic diseases.

Location
South San Francisco, California, USA
Founded
2011
Categories
biotech, neurology, complement, autoimmune, ophthalmology

Notes

Annexon Biosciences is a clinical-stage biopharmaceutical company advancing a pipeline of first-in-class therapies for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic diseases. The company's lead candidate, ANX005, is an anti-C1q antibody being developed for Guillain-Barré syndrome, Huntington's disease, and other conditions.

The classical complement pathway, initiated by C1q, has been implicated in various diseases involving neurodegeneration and autoimmune-mediated tissue destruction. By inhibiting C1q, Annexon aims to prevent downstream complement activation and tissue damage.

Team

  • Douglas Love - President & Chief Executive Officer
  • Ted Yednock, Ph.D. - Co-founder & Former CSO
  • Arnon Bhbat, Ph.D. - Co-founder

Additional Research Findings

  • In Bain Capital Life Sciences portfolio
  • Publicly traded on NYSE (ticker: ANNX)
  • Lead candidate ANX005 (anti-C1q antibody) in clinical development
  • Programs for Guillain-Barré syndrome, Huntington's disease
  • ANX007 for geographic atrophy (GA) in ophthalmology
  • Classical complement C1q-targeted approach
  • Headquarters in South San Francisco, CA

Sources